Neurolief said on November 18 that it has secured single-case agreements with U.S. payers for ProlivRx, one of two at-home depression devices FDA approved in December 2025, and that it is accepting prescriptions from any clinician whose patient wants insurance coverage. The company calls this a commercial reimbursement pathway.
That is progress in a device class with no established way to pay for it. A single-case agreement is a payer’s decision to cover a treatment for one named patient; in Neurolief’s own description, it applies to therapies “not yet part of a health plan’s standard coverage policy.” The company has not named a payer, said how many agreements exist, or said whether any claim has been paid. The policies point the other way: the two payer policies Behavioral Wire read in full that address cranial electrical stimulation, from Aetna and Geisinger Health Plan, were both reviewed in July 2026. Both still treat the category as unproven, and neither names either approved device.
Two approvals, 23 days apart
FDA approved Flow Neuroscience’s FL-100 on December 8, 2025 and ProlivRx on December 31. Both are Class III devices under product code JXK, a cranial electrotherapy stimulator to treat depression, and FDA’s premarket approval database lists no other original approval under that code. The indications differ. FL-100 is for moderate to severe depression in patients not considered treatment-refractory. ProlivRx is an adjunct for adults who did not improve enough on at least one antidepressant, at home or in clinic.
Approval does not create a payment route. Behavioral Wire found no CPT or HCPCS code that identifies either device. Codes exist for the category: HCPCS K1002 for a cranial electrotherapy stimulation system of any type, A4596 for its monthly supplies, and E1399, the miscellaneous equipment code. Geisinger’s policy lists K1002 and E1399 and also excludes the category from coverage. Neurolief has not said which code its agreements use. Behavioral Wire also found no Medicare national coverage determination for cranial electrical stimulation. CMS retired its determination on electrosleep therapy, a name Aetna’s policy lists for the category, effective January 1, 2021, which left decisions to regional Medicare contractors.
What an agreement covers is unknown too. FDA’s summary and the approved user manual describe a headset with a three-year lifetime, replaceable electrode pads, a mobile app that controls the device and a cloud platform that reports adherence to the treating clinician, used under physician supervision for 8 to 16 weeks. Equipment, supplies, software and clinician time are not usually billed the same way.
What an agreement does and does not do
A single-case agreement is an insurer’s decision about one named patient. It creates no network contract, no coverage policy and no obligation to the next member who asks. Behavioral Wire found no public benchmark for how often such agreements are granted for new devices or what they pay.
Neurolief says it does the work itself.
“Our team works directly with the providers and the payers on each patient’s behalf, from documenting medical necessity and submitting prior authorization requests to supporting appeals if a request is denied.”
— Scott Drees, chief executive of Neurolief, in the company’s November 18 announcement
That is a manufacturer running a reimbursement desk patient by patient, appeals included. It is an expensive way to be paid and a credible way to start in a new device category. It also suggests where the category stands: appeals support is what a treatment needs when payers have not yet decided to cover it.
The VA, and BrainsWay’s stake
The VA came first. Neurolief announced a VA contract on August 11, saying multiple VA medical centers are prescribing ProlivRx and its migraine device, Relivion MG. BrainsWay, the TMS maker that holds $11 million of Neurolief convertible loans and an option to acquire the company, said in May that Neurolief had a Federal Supply Schedule contract with VA-approved pricing of $11,800 per unit. That price comes from Neurolief’s lender describing its investee, not from a published schedule listing.
A VA contract answers a procurement question for one buyer. A commercial medical director faces a different one: whether to write a policy covering every member who meets its criteria. Neurolief’s revenue also matters to BrainsWay (BWAY), whose agreement provides a third investment of up to $5 million if Neurolief reaches $10 million in trailing 12-month revenue. On BrainsWay’s November 10 call, its chief executive said ProlivRx commercialization remains at an early stage and that he sees “very good progress” in distribution, including through VA channels and some of BrainsWay’s clinics.
What the trial supports
The approval rests on a peer-reviewed trial. The pivotal MOOD study randomized 126 patients at 13 sites in the United States and Israel to eight weeks of active or sham stimulation, followed by eight weeks of open-label active treatment. Two patients under 22 were counted only in safety reporting, leaving 124 in the intent-to-treat set, 62 per arm. The study met its primary endpoint: on the 17-item Hamilton depression scale, active treatment lowered scores by an adjusted mean of 8.62 points against 6.01 for sham, a 2.61-point difference (p = 0.0196). It was published in Brain Stimulation in 2025.
The protocol pre-specified the primary analysis for a modified intent-to-treat set: the 97 patients, 47 of 62 active and 50 of 62 sham, who completed at least 1,680 minutes of stimulation, the equivalent of 40 minutes a day, five days a week for eight weeks, with no post-randomization exclusion, analyzed as treated. FDA’s summary words the finding for patients who used the device as directed, and the user manual spells out the definition. The trial met its endpoint in the population it specified. A payer deciding coverage for everyone who is prescribed the device is looking at evidence from the patients who met that usage threshold.
Remission, a Hamilton score of 7 or below, was a secondary outcome: 10 of 47 active patients against 3 of 50 sham at eight weeks, 21.3 percent against 6.0 percent, a gap of about 15 percentage points. The published paper reports that difference as significant (p = 0.027). FDA’s summary says that across the secondary outcomes, analyzed with a prespecified adjustment for multiple comparisons, the active arm had a numerical advantage but none reached the 0.05 threshold. Response, a 50 percent score reduction, was 15 of 47 against 9 of 50 and is not in the company’s release. The 31.7 percent remission figure the release gives for 16 weeks comes from the open-label phase, after the sham group crossed over, so it has no comparator.
The economic case is made separately. Neurolief’s site for health systems and payers cites an estimated $35,000 in annual savings per patient, based on actuarial analyses and driven by fewer escalations to clinic-based neuromodulation, emergency visits and inpatient use. No model or assumptions are published, and FDA’s summary of the trial reports no utilization or cost outcome. It is a company estimate that the trial neither supports nor contradicts.
What would turn an exception into coverage
An exception pathway and a reimbursement pathway are different things. Five developments would show the change: a named payer publishing a standing coverage policy that applies to any member who meets its criteria; the same payer approving a second and third member on the same reasoning; disclosed paid claims, not only authorizations; a billing code that identifies the device instead of routing it through category or miscellaneous codes; and a Medicare coverage decision. None has been disclosed or located for either approved device.
The first checkable sign will be a payer policy that names ProlivRx or FL-100 in its criteria, or a Neurolief disclosure of a paid claim.